Derrick Hall JD, PharmD, MBA Integra

**Christie Smith PharmD, MBA** 

Sr. Director, Payer Initiatives, AmerisourceBergen

Integrate to innovate—
how effective payer and provider
collaboration improves cancer care



Christie is the Senior Director, Payer Initiatives at Specialty Physician Services & Solutions division of AmerisourceBergen (AB). She serves as a payer resource to Community Oncology Practices and AB. She is committed to helping Community Oncology Practices increase their access to payer contracts through the creation of payer partnerships, improve reimbursement when possible, and assist in navigating the complex payer landscape. Smart ID Works is now under her leadership.

Christie earned her Bachelor of Science in Pharmacy from University of Texas at Austin, her MBA from University of Dallas, and Doctorate of Pharmacy (PharmD) from University of Florida. She has certifications in Sterile IV Admixture, and Medication Therapy Management. She is licensed to practice pharmacy in the state of Texas.

Christie's 29-year career includes pharmacy practice experiences at Kaiser Permanente Oncology Outpatient Clinics and Retail, Hospital, Specialty, & Home Infusion Pharmacies; she ran a specialty pharmacy practice and business at legacy Caremark Specialty Pharmacy; she presented compelling clinical and financial data trends & solutions to HR Leaders & Executives to influence pharmacy benefit plans of national employer groups at Legacy Aetna Pharmacy Management; she taught pharmacology to pharmacy technicians at Richland College; she designed clinical programs & managed payer contracts for two large government payers - United States Marshal Services & Veteran's Administration; and as an entrepreneur she has performed private consulting at The Pharmacy Care Team.

Christie has a very rich background, and we are happy to have her lead our Payer Solutions team at AB.

She resides in Flower Mound (a suburb of Dallas, TX) with her husband of 32 years and two young adult children. Christie works remotely for AB.




# Agenda

- 1. Background and current state of Medically Integrated Dispensing (MID) in Oncology
- 2. What is your payer strategy?
- 3. New payer models:
- Elevate Retail PSAO IntegratedRx
- Accelerate Specialty PSAO
- 4. Conclusion

# The current landscape of oncology medications

\*35% of all new therapies are being formulated in oral dosing form



<sup>\*</sup>Asembia Specialty Summit



#### Faster access to care

Enables easier & faster start times for patients needing to begin a course of medication without multiple contacts with third parties


#### Increase adherence & decrease waste

Increase patient adherence by providing ease of access to needed therapies. Reduces pharmaceutical waste by integrating the dispensing of medications with scheduled scans.

#### Decrease overall cost of care

Lower total cost of care through real time access of the medical records at the time of dispensing and medication therapy management by onsite pharmacists

What is your payer strategy?





# IntegratedRx<sup>TM</sup>


A novel clinically integrated oncology network

Prime Therapeutics and AmerisourceBergen


## Concept overview

**Market Problem:** The existing PBM-SP model does not fully address patient outcomes, cost-efficiency, and transparency needs of plans and patients. Virtually all oncology scripts covered under commercial pharmacy benefits are dispensed by PBM-affiliated SPs (except first fills in some cases). PBMs send scripts into their own specialty pharmacies and create pricing incentives to plans to conform benefit designs to their model.

# **Existing model** for oral oncology drugs (pharmacy benefit)



# **New proposed model** for oral oncology drugs (pharmacy benefit)



The Prime Network will be a **first-of-its kind PBM offering** that could reshape how the medication needs of complex specialty patients are addressed through **deeper relationships with local providers**, versus the traditional PBM-affiliated SP model.

#### 4

## Key elements of the medically integrated network payer model

What


Pharmacy network consisting of community oncologists and health systems across Prime Therapeutics payer customers vs. traditional PBM-SP network for specified oral oncology drugs covered under the pharmacy benefit

#### Details

- Limited to oncology today, but will be expanded to other therapeutic categories
- Limited to commercial Blues plans today, but with proof of concept can be expanded to other Blue plans and payers
- Participation Requirements: Participation incumbent upon data sharing and obtaining ACHC, URAC, NCODA accreditation within 1 year of participating
- Pricing:
  - Phase 1 Competitive brand and generic effective rates
  - Phase 2 Valued Based Model
- Distributors Participating: AB, McKesson
- The first market to go live was Horizon Blue Cross 10/1/22;
   Initial agreement through 2024

Prime Network Clients	State	
BCBSAL	AL	
Florida Blue	FL	
BCBSMN	MN	
BCBSNC	NC	
Horizon BCBS NJ	NJ	
Capital Blue Cross - CBC	PA	
BCBSRI	RI	
BCBSIL (HCSC)	IL	
BCBSNM (HCSC)	NM	
BCBSOK (HCSC)	OK	
BCBSTX (HCSC)	TX	
BCBSMT (HCSC)	MT	
BCBSKS	KS	
BCBSND	ND	
BCBSNE	NE	
BCBSWY	WY	
Cambia	OR, WA, ID, UT	

# IntegratedRx™ is designed to optimize value



#### 9

## Prime Therapeutics medically integrated plans by go-live date

Go-Live Date	Plan (s)	AB Market (s)
October 1, 2021	BCBS Horizon	New Jersey
January 1, 2022	Cambia Plans of Washington, Utah, Oregon, & Idaho, BCBS Kansas, BCBS Minnesota, BCBS Nebraska	Washington, Utah, Idaho, <b>Oregon, Kansas, Minnesota,</b> Nebraska
April 1, 2022	BCBS of Illinois, BCBS of Texas, BCBS New Mexico*	Illinois, Texas, New Mexico
May 1, 2022	BCBS of North Carolina (ASO only)	North Carolina
January 1, 2023	BCBS of North Dakota, BCBS of Montana, BCBS of Oklahoma, Academic Health Plan (AHP)	North Dakota, Montana, Oklahoma, Texas, California
TBD	Capital Blue Cross, BCBS Alabama, Florida Blue**	Pennsylvania, Alabama, Florida

\*Blue Cross Blue Shield of Rhode Island and Wyoming are not participating in IntegratedRx\*

\*\*Florida Blue declined participation in 2023\*\*



# Innovation with Prime Therapeutics

- AB is a pioneer and industry leader in MID
- Relationship building with payer
- Alignment on goals
- Payer experience
- Contracting experience
- Leakage reporting
- Value based concepts
- Shift in the marketplace to MID over specialty pharmacies
- Accreditation support
- Outcomes data

**Accelerate Specialty Network** 

Specialty PSAO for medically integrated dispensing practices

## Integrating capabilities to go beyond retail contracts

The nation's first specialty-focused PSAO

#### Market-leading retail PSAO

**Elevate Provider Network** 

50+

PBMs contracted

5,000+

#### Actionable analytics

and technology solutions to empower better business decision making



Specialty distribution leadership AmerisourceBergen

One of the largest distributors of specialty pharmaceuticals

serves nearly

100%

of U.S. hospitals with specialty medications

#### Innovative solutions

for health system specialty pharmacies to maximize performance

Accelerate Specialty Network

# We support a unique network of medically-integrated and strategic independent specialty pharmacies

Our network combines diverse specialty pharmacies to achieve community focus at a national scale

# Health system specialty pharmacies

Larger health systems and IDNs with specialty pharmacy capabilities



## Medically integrated dispensing practices

Large specialty physician practices with in-office dispensing capabilities

Strategic independent specialty pharmacies

Patient-centric specialty pharmacies with no payer or extra organizational ownership

#### **Our MID members**

**AON Pharmacy** 

The Blood and Cancer Center

**California Cancer Associates** 

**Cancer Care Specialists of Central Illinois** 

Cancer and Hematology Centers of Western Michigan

**Carolina Blood and Cancer Associates** 

**Cancer Specialist of North Florida** 

**Hematology-Oncology Associates of CNY** 

**Illinois Cancer Care** 

**The Oncology Institute** 

Accelerate Specialty
Network is **the** nation's first
PSAO for community-based
specialty pharmacy practices

Let's face it, we're in an evolving market accompanied with rising reimbursement pressures and shrinking margins.

Accessing beneficial payer contracts – especially for specialty medications – has never been more challenging.

Accelerate was built to tackle these challenges head on.

Leveraging our deep industry experience and PSAO

expertise, we've created the industry's first specialty PSAO.

**Network overview\*** 

2021

launched to the market

80

specialty pharmacies

11


PBMs contracted

23MM+

commercial covered lives

### Operationalizing the network

Claim flow and secondary submission process





Conclusion



# Medically Integrated Dispensing program

- Improve outcomes through better compliance and side effect management
- Forge new avenues for growth while creating a comprehensive care environment
- Insurance companies are driving more items to the pharmacy benefit
- Showcase provider quality measurements under value-based care model
- Improve patient ease and start of access to life changing medications
- Create a more comprehensive care setting to attract new patients





# We believe in the power of medically integrated care

That's why we actively promote the value of medically integrated dispensing practices to help improve the access, value, and delivery of quality care for patients receiving specialty medications.

# Through partnerships across the AmerisourceBergen enterprise, our focus is 5–fold:

- Facilitate conversations with industry experts and peers to identify value driving innovation opportunities
- 2. Leverage **advanced analytics** to help prove the cost of care reduction achieved by prioritizing clinically coordinated care
- 3. Advocate for our practices and patients
- 4. Optimize payer and product access
- 5. Support the viability & sustainability of community oncology



Q&A